Nexviadyme (Avalglucosidase Alfa)

Nexviadyme is employed in the management of lysosomal storage disorders, specifically targeting Pompe disease (glycogen storage disease type II).

• Infantile‑onset Pompe disease: improves survival, cardiac function, and motor development by reducing glycogen accumulation in cardiac and skeletal muscle.
• Late‑onset Pompe disease: stabilizes respiratory function and slows progression of muscle weakness, enhancing quality of life.
• Confirmed acid alpha‑glucosidase deficiency: restores enzymatic activity in lysosomes, facilitating normal glycogen breakdown and reducing disease‑related complications.

• Avalglucosidase Alfa is a recombinant human acid alpha‑glucosidase enzyme that replaces the deficient endogenous enzyme in patients with Pompe disease. After intravenous infusion, the protein is taken up by mannose‑6‑phosphate receptors on the surface of affected cells, traffics to lysosomes, and hydrolyzes accumulated glycogen into glucose, thereby restoring normal lysosomal function and reducing cellular damage.

Nexviadyme may be associated with a range of adverse reactions observed in clinical use.

Common Side Effects

• Infusion‑related reactions: flushing, chills, fever, or headache during or shortly after administration.
• Gastrointestinal disturbances: nausea, vomiting, abdominal pain, or diarrhea.
• Respiratory symptoms: cough, dyspnea, or upper respiratory tract infection.
• Musculoskeletal pain: joint or muscle aches.
• Fatigue or malaise.

Serious or Rare Side Effects

• Anaphylaxis or severe hypersensitivity reactions requiring emergency treatment.
• Cardiac arrhythmias or worsening heart failure.
• Severe respiratory compromise requiring mechanical ventilation.
• Thrombotic events or deep vein thrombosis.
• Renal impairment or acute kidney injury.

When prescribing Nexviadyme, clinicians should observe several precautionary measures to ensure patient safety.

• Assess baseline cardiac and respiratory function: evaluate echocardiogram and pulmonary tests before initiating therapy.
• Monitor for infusion reactions: observe patients during and after infusion for signs of hypersensitivity.
• Check liver enzymes: perform periodic hepatic function tests during treatment.
• Evaluate renal function: assess serum creatinine and glomerular filtration rate regularly.
• Avoid use in patients with known severe hypersensitivity to the product or its excipients.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Nexviadyme can interact with other medicines; awareness of these interactions helps manage risk.

Major Interactions (Avoid)

• Live vaccines: concurrent administration may increase risk of infection due to immune modulation.
• High‑dose immunosuppressants: may diminish therapeutic efficacy of enzyme replacement.

Moderate Interactions (Monitor Closely)

• Antihistamines or corticosteroids: may mask or reduce severity of infusion‑related reactions.
• ACE inhibitors or diuretics: require monitoring of blood pressure and renal function during therapy.
• Concomitant enzyme therapies: assess for additive immunogenicity or overlapping adverse profiles.